Diagnostic value of serum miR197 and miR145 in non‑small cell lung cancer

Sui,Ankui; Zhang,Xifeng; Zhu,Qing

doi:10.3892/ol.2019.9958

Diagnostic value of serum miR197 and miR145 in non‑small cell lung cancer

Authors:
- Ankui Sui
- Xifeng Zhang
- Qing Zhu
View Affiliations

Affiliations: Department of Oncology, Jimo Hospital of Traditional Chinese Medicine, Qingdao, Shandong 266200, P.R. China, Department of Infectious Disease, The People's Hospital of Jimo District, Qingdao, Shandong 266200, P.R. China
Published online on: January 23, 2019 https://doi.org/10.3892/ol.2019.9958
Pages: 3247-3252
Copyright: © Sui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diagnostic value of microRNA (miR)‑197 and miR‑145 in non‑small cell lung cancer (NSCLC) and their relationship with the clinicopathological parameters of NSCLC patients were investigated. Seventy‑six patients with NSCLC admitted to Jimo Hospital of Traditional Chinese Medicine from July 2016 to March 2018 were enrolled in group A, while 60 healthy who received health examinations during the same period were enrolled in group B. The relative expression levels of serum miR‑197 and miR‑145 were detected by RT‑qPCR. The relative expression of serum miR‑197 in group A was significantly higher than that in group B (P<0.001); the relative expression of serum miR‑145 in group A was significantly lower than that in group B (P<0.001); serum miR‑197 in group A showed association with the clinical stage of NSCLC patients (P<0.001); serum miR‑145 in group A was associated with the clinical stage and pathological differentiation of patients with NSCLC (P<0.001). The AUC of serum miR‑197 diagnosis of NSCLC was 0.864 (95% CI: 0.804‑0.924), with a diagnostic sensitivity of 73.68% and a specificity of 85.00%; the AUC of serum miR‑145 diagnosis of NSCLC was 0.879 (95% CI: 0.824‑0.934), with a diagnostic sensitivity of 84.21% and a specificity of 71.67%; the AUC of the diagnosis of the combination of serum miR‑197 and miR‑145 for NSCLC was 0.952 (95% CI: 0.919‑0.984), with a diagnostic sensitivity of 92.10% and a specificity of 78.33%. miR‑197 and miR‑145 are potential new biomarkers in the diagnosis of NSCLC due to their possible involvement in the occurrence and development of NSCLC. With good sensitivity and specificity of single miR‑197 and single miR‑145 for the diagnosis of NSCLC, the combined detection of miR‑197 and miR‑145 can achieve a better sensitivity in the diagnosis of NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hou J, Meng F, Chan LW, Cho WC and Wong SC: Circulating plasma microRNAs as diagnostic markers for NSCLC. Front Genet. 7:1932016. View Article : Google Scholar : PubMed/NCBI
3	Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, Liu X, Le H and Zhang Y: Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS One. 11:e01530462016. View Article : Google Scholar : PubMed/NCBI
4	Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F and Tonato M: Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 95:1453–1461. 2003. View Article : Google Scholar : PubMed/NCBI
5	Navani N, Nankivell M, Lawrence DR, Lock S, Makker H, Baldwin DR, Stephens RJ, Parmar MK, Spiro SG, Morris S, et al Lung-BOOST trial investigators, : Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: An open-label, pragmatic, randomised controlled trial. Lancet Respir Med. 3:282–289. 2015. View Article : Google Scholar : PubMed/NCBI
6	Bonatti M, Vezzali N, Lombardo F, Ferro F, Zamboni G, Tauber M and Bonatti G: Gallbladder adenomyomatosis: Imaging findings, tricks and pitfalls. Insights Imaging. 8:243–253. 2017. View Article : Google Scholar : PubMed/NCBI
7	Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD; National Lung Screening Trial Research Team, : Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
8	Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
9	Mehta AK, Hua K, Whipple W, Nguyen MT, Liu CT, Haybaeck J, Weidhaas J, Settleman J and Singh A: Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Sci Signal. 10:102017. View Article : Google Scholar
10	Wang RJ, Zheng YH, Wang P and Zhang JZ: Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 8:765–771. 2015.PubMed/NCBI
11	Mavridis K, Gueugnon F, Petit-Courty A, Courty Y, Barascu A, Guyetant S and Scorilas A: The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients. Br J Cancer. 112:1527–1535. 2015. View Article : Google Scholar : PubMed/NCBI
12	Skjefstad K, Johannessen C, Grindstad T, Kilvaer T, Paulsen EE, Pedersen M, Donnem T, Andersen S, Bremnes R, Richardsen E, et al: A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer. Sci Rep. 8:85492018. View Article : Google Scholar : PubMed/NCBI
13	Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al ESMO Guidelines Committee, : Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27 Suppl 5:v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Guisier F, Salaün M, Lachkar S, Lamy A, Piton N, Obstoy B, Sabourin JC and Thiberville L: Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS. Respirology. 21:718–726. 2016. View Article : Google Scholar : PubMed/NCBI
16	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
17	Montani F, Marzi MJ, Dezi F, Dama E, Carletti RM, Bonizzi G, Bertolotti R, Bellomi M, Rampinelli C, Maisonneuve P, et al: miR-Test: A blood test for lung cancer early detection. J Natl Cancer Inst. 107:djv0632015. View Article : Google Scholar : PubMed/NCBI
18	Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
19	Molina R, Marrades RM, Augé JM, Escudero JM, Viñolas N, Reguart N, Ramirez J, Filella X, Molins L and Agustí A: Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med. 193:427–437. 2016. View Article : Google Scholar : PubMed/NCBI
20	Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, et al: Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res. 14:7813–7821. 2008. View Article : Google Scholar : PubMed/NCBI
21	Xie X, Liu HT, Mei J, Ding FB, Xiao HB, Hu FQ, Hu R and Wang MS: miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. Int J Clin Exp Pathol. 8:3827–3834. 2015.PubMed/NCBI
22	Nadal E, Truini A, Nakata A, Lin J, Reddy RM, Chang AC, Ramnath N, Gotoh N, Beer DG and Chen G: A novel serum 4-microRNA signature for lung cancer detection. Sci Rep. 5:124642015. View Article : Google Scholar : PubMed/NCBI
23	Zuberi M, Khan I, Mir R, Gandhi G, Ray PC and Saxena A: Utility of serum miR-125b as a diagnostic and prognostic indicator and its alliance with a panel of tumor suppressor genes in epithelial ovarian cancer. PLoS One. 11:e01539022016. View Article : Google Scholar : PubMed/NCBI
24	Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M and De Maria R: Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 21:774–782. 2014. View Article : Google Scholar : PubMed/NCBI
25	Yang Y, Li F, Saha MN, Abdi J, Qiu L and Chang H: miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res. 21:2399–2411. 2015. View Article : Google Scholar : PubMed/NCBI
26	Pekow J, Meckel K, Dougherty U, Butun F, Mustafi R, Lim J, Crofton C, Chen X, Joseph L and Bissonnette M: Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon. Am J Physiol Gastrointest Liver Physiol. 308:G179–G187. 2015. View Article : Google Scholar : PubMed/NCBI
27	Xie H, Ren X, Xin S, Lan X, Lu G, Lin Y, Yang S, Zeng Z, Liao W, Ding YQ, et al: Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. Oncotarget. 7:26680–26691. 2016.PubMed/NCBI
28	Mo D, Yang D, Xiao X, Sun R, Huang L and Xu J: MiRNA-145 suppresses lung adenocarcinoma cell invasion and migration by targeting N-cadherin. Biotechnol Lett. 39:701–710. 2017. View Article : Google Scholar : PubMed/NCBI
29	Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD, et al: miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 7:1234–1243. 2009. View Article : Google Scholar : PubMed/NCBI
30	Shen H, Shen J, Wang L, Shi Z, Wang M, Jiang BH and Shu Y: Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. Biomed Pharmacother. 69:301–305. 2015. View Article : Google Scholar : PubMed/NCBI
31	Shaker O, Maher M, Nassar Y, Morcos G and Gad Z: Role of microRNAs −29b-2, −155, −197 and −205 as diagnostic biomarkers in serum of breast cancer females. Gene. 560:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
32	Liang H, Jiang Z, Xie G and Lu Y: Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumour Biol. 36:5305–5313. 2015. View Article : Google Scholar : PubMed/NCBI